Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.810
-0.080 (-4.23%)
At close: Oct 30, 2026, 4:00 PM EDT
1.870
+0.060 (3.31%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending June 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%. That makes Pyxis Oncology the 36,903rd largest company in the world by revenue and 4,845th in the United States.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
19.59
Revenue / Employee
$197,107
Employees
56
Market Cap
216.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 229.28M |
| Protalix BioTherapeutics | 80.62M |
| Precision BioSciences | 45.06M |
| AC Immune | 21.67M |
| Keros Therapeutics | 15.01M |
| Evommune | 10.00M |
| Camp4 Therapeutics | 4.22M |
| Sol-Gel Technologies | 1.80M |
PYXS News
- 3 days ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 10 days ago - Pyxis Oncology Proxy statement: Proxy filing - Filings
- 22 days ago - Pyxis Oncology Proxy statement: Proxy filing - Filings
- 4 weeks ago - Pyxis Oncology announces closing of up to $282.6M public offering - TheFly
- 4 weeks ago - Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology 36M share Spot Secondary priced at $2.90 - TheFly
- 4 weeks ago - Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering - GlobeNewsWire